| Name | Title | Contact Details |
|---|
Neurotech Pharmaceuticals, Inc. is a Lincoln, RI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CNS Therapeutics is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kyn Therapeutics is building a new generation of immuno-oncology therapies targeting powerful immunosuppressive metabolic networks. We envision a future where immunotherapies are the foundation of every cancer patient`s treatment, delivering rapid and durable responses. The Kyn team is composed of drug hunters, translational researchers and entrepreneurs drawn from many of the largest innovators in biotechnology supported by world-class advisors, and is backed by a seasoned board of directors anchored by OrbiMed Healthcare Fund Management and Atlas Venture. Kyn Therapeutics is headquartered in the biotech hub of Cambridge, Massachusetts.
ZielBio is an early-stage biotechnology company that identifies novel high value disease targets and develops therapeutic interventions to improve patient outcomes. Our proprietary drug discovery platform Zielfind™ combines the power of functional, high throughput screening with large content data analytics to identify high value targets. We have a promising pipeline of therapies and targets, including lead compound ZB131, a proprietary humanized monoclonal antibody against cell surface plectin (CSP) a cancer target identified through Zielfind™.
Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company`s most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus. Olvi-Vec currently is being evaluated in OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination with platinum-doublet + bevacizumab compared to platinum-doublet + bevacizumab in patients with platinum-resistant/refractory ovarian cancer. The core of Genelux` discovery and development efforts revolves around the company`s proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.